Publications by authors named "Robert C Grenn"
Article Synopsis
- Some people with lupus have special antibodies that can make blood clots more likely, which is a problem called antiphospholipid syndrome (APS).
- Neutrophils, a type of white blood cell, are important in causing these blood clots, and scientists studied their genes to understand how they behave in APS.
- A specific protein called PSGL-1 on neutrophils can help these cells stick to blood vessels and create clots, suggesting that targeting PSGL-1 might help treat APS patients.
Objectives: Patients with antiphospholipid syndrome (APS) are at risk for subclinical endothelial injury, as well as accelerated atherosclerosis. In the related disease systemic lupus erythematosus, there is a well-established defect in circulating endothelial progenitors, which leads to an accrual of endothelial damage over time. This defect has been at least partially attributed to exaggerated expression of type I interferons (IFNs).
View Article and Find Full Text PDFRationale: Neutrophil extracellular trap (NET) formation promotes vascular damage, thrombosis, and activation of interferon-α-producing plasmacytoid dendritic cells in diseased arteries. Peptidylarginine deiminase inhibition is a strategy that can decrease in vivo NET formation.
Objective: To test whether peptidylarginine deiminase inhibition, a novel approach to targeting arterial disease, can reduce vascular damage and inhibit innate immune responses in murine models of atherosclerosis.